[{"id":"28c966c6-aa0a-48ec-89d0-5286ecccf723","acronym":"","url":"https://clinicaltrials.gov/study/NCT02912559","created_at":"2021-01-18T14:17:52.733Z","updated_at":"2025-02-25T12:26:32.593Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair","source_id_and_acronym":"NCT02912559","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MLH1 • MSH6 • MSH2 • CD4","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MLH1 • MSH6 • MSH2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • 5-fluorouracil • Cotellic (cobimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 10/16/2017","start_date":" 10/16/2017","primary_txt":" Primary completion: 04/02/2025","primary_completion_date":" 04/02/2025","study_txt":" Completion: 04/02/2025","study_completion_date":" 04/02/2025","last_update_posted":"2025-02-24"},{"id":"d9249df0-7324-4379-b412-dbfbc6b5d9e8","acronym":"NAUTIKA1","url":"https://clinicaltrials.gov/study/NCT04302025","created_at":"2021-01-18T20:51:55.005Z","updated_at":"2025-02-25T13:40:05.730Z","phase":"Phase 2","brief_title":"A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04302025 - NAUTIKA1","lead_sponsor":"Genentech, Inc.","biomarkers":" PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12","tags":["PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Cotellic (cobimetinib) • Gavreto (pralsetinib) • divarasib (RG6330)"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 03/06/2029","study_completion_date":" 03/06/2029","last_update_posted":"2025-02-21"},{"id":"2223e62c-2304-4f09-b793-71e2fb24f5a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03224767","created_at":"2021-04-28T13:53:13.407Z","updated_at":"2025-02-25T14:15:02.976Z","phase":"Phase 2","brief_title":"Vemurafenib and Cobimetinib in Treating Patients with BRAF V600E Mutation Positive Craniopharyngioma","source_id_and_acronym":"NCT03224767","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CYP1A2","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 01/05/2018","start_date":" 01/05/2018","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-02-18"},{"id":"6d9c9dc1-5735-46b5-bfc4-9aa69eeeef0c","acronym":"BFAST","url":"https://clinicaltrials.gov/study/NCT03178552","created_at":"2021-01-18T15:40:25.224Z","updated_at":"2025-02-25T15:17:28.532Z","phase":"Phase 2/3","brief_title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03178552 - BFAST","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF • TMB","pipe":"","alterations":" ","tags":["BRAF • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • carboplatin • gemcitabine • Rozlytrek (entrectinib) • docetaxel • Alecensa (alectinib) • Cotellic (cobimetinib) • pemetrexed • divarasib (RG6330)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 09/22/2017","start_date":" 09/22/2017","primary_txt":" Primary completion: 08/03/2028","primary_completion_date":" 08/03/2028","study_txt":" Completion: 08/03/2028","study_completion_date":" 08/03/2028","last_update_posted":"2025-02-12"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"eda22fa5-a154-4718-aaaf-d2fb8460e402","acronym":"","url":"https://clinicaltrials.gov/study/NCT02721459","created_at":"2021-01-18T13:18:50.231Z","updated_at":"2025-02-25T16:30:48.412Z","phase":"Phase 1","brief_title":"XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma","source_id_and_acronym":"NCT02721459","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib) • XL888"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 09/07/2016","start_date":" 09/07/2016","primary_txt":" Primary completion: 10/31/2019","primary_completion_date":" 10/31/2019","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2025-02-07"},{"id":"e098103f-75c1-4aa9-b386-41c1d51fb602","acronym":"MATCH","url":"https://clinicaltrials.gov/study/NCT03155620","created_at":"2021-01-18T15:33:32.929Z","updated_at":"2025-02-25T16:51:52.930Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","source_id_and_acronym":"NCT03155620 - MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2316","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-04"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"613dfa54-e318-471f-a8ed-a12b2572968b","acronym":"CAPTUR","url":"https://clinicaltrials.gov/study/NCT03297606","created_at":"2021-01-18T16:17:30.914Z","updated_at":"2025-02-25T13:52:23.697Z","phase":"Phase 2","brief_title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","source_id_and_acronym":"NCT03297606 - CAPTUR","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • sunitinib • Perjeta (pertuzumab) • Cotellic (cobimetinib) • bosutinib • Tukysa (tucatinib) • temsirolimus • axitinib • Erivedge (vismodegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-11-12"},{"id":"1a2869b0-2430-4d5c-ab76-f7ab8c14388e","acronym":"IMPROVEMENT-2","url":"https://clinicaltrials.gov/study/NCT06603376","created_at":"2025-02-27T08:21:36.373Z","updated_at":"2025-02-27T08:21:36.373Z","phase":"Phase 2","brief_title":"Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer","source_id_and_acronym":"NCT06603376 - IMPROVEMENT-2","lead_sponsor":"Shanghai Changzheng Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Zelboraf (vemurafenib) • 5-fluorouracil • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-09-19"},{"id":"e654c874-ff26-4818-92d4-ab360c653d3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05068752","created_at":"2021-10-06T12:53:53.320Z","updated_at":"2025-02-25T17:25:17.327Z","phase":"Phase 2","brief_title":"Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer","source_id_and_acronym":"NCT05068752","lead_sponsor":"HonorHealth Research Institute","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • sorafenib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/28/2021","start_date":" 10/28/2021","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-09-19"},{"id":"03fa7b60-29a0-4a44-aa05-14a8b5df45eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02091141","created_at":"2021-01-17T17:15:36.027Z","updated_at":"2025-02-25T12:26:06.921Z","phase":"Phase 2","brief_title":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT02091141","lead_sponsor":"Genentech, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation","tags":["EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • erlotinib • Zelboraf (vemurafenib) • Alecensa (alectinib) • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 673","initiation":"Initiation: 04/14/2014","start_date":" 04/14/2014","primary_txt":" Primary completion: 05/24/2023","primary_completion_date":" 05/24/2023","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2024-07-23"},{"id":"0c9f5f05-6df2-4534-8291-c2ac3324cb6a","acronym":"AcSé","url":"https://clinicaltrials.gov/study/NCT02304809","created_at":"2021-01-17T17:46:46.183Z","updated_at":"2024-07-02T16:34:37.044Z","phase":"Phase 2","brief_title":"Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations","source_id_and_acronym":"NCT02304809 - AcSé","lead_sponsor":"UNICANCER","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 216","initiation":"Initiation: 10/13/2014","start_date":" 10/13/2014","primary_txt":" Primary completion: 05/07/2019","primary_completion_date":" 05/07/2019","study_txt":" Completion: 10/13/2027","study_completion_date":" 10/13/2027","last_update_posted":"2024-06-07"},{"id":"7ee65b79-49ff-449c-ae18-0e2f8ded36d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06440850","created_at":"2024-06-08T04:18:06.782Z","updated_at":"2024-07-02T16:34:59.043Z","phase":"Phase 2","brief_title":"Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation","source_id_and_acronym":"NCT06440850","lead_sponsor":"City of Hope Medical Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 11/30/2024","start_date":" 11/30/2024","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-06-04"},{"id":"66295375-7bb9-499f-9a29-4931cfd6243c","acronym":"NeoACTIVATE","url":"https://clinicaltrials.gov/study/NCT03554083","created_at":"2021-01-18T17:29:17.667Z","updated_at":"2024-07-02T16:35:01.056Z","phase":"Phase 2","brief_title":"Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma","source_id_and_acronym":"NCT03554083 - NeoACTIVATE","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600 • BRAF wild-type","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Cotellic (cobimetinib) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/05/2018","start_date":" 10/05/2018","primary_txt":" Primary completion: 06/29/2025","primary_completion_date":" 06/29/2025","study_txt":" Completion: 06/29/2025","study_completion_date":" 06/29/2025","last_update_posted":"2024-05-24"},{"id":"b30b1e44-f866-4d50-98ee-25a4b13b78d0","acronym":"ImmunoCobiVem","url":"https://clinicaltrials.gov/study/NCT02902029","created_at":"2021-03-22T16:53:54.040Z","updated_at":"2024-07-02T16:35:01.852Z","phase":"Phase 2","brief_title":"Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma","source_id_and_acronym":"NCT02902029 - ImmunoCobiVem","lead_sponsor":"University Hospital, Essen","biomarkers":" PD-1","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Completed","enrollment":" Enrollment 186","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2024-05-23"},{"id":"d8059b4f-3b03-40aa-8b9b-b4fdbc881145","acronym":"","url":"https://clinicaltrials.gov/study/NCT01709292","created_at":"2021-01-18T07:26:46.450Z","updated_at":"2024-07-02T16:35:02.453Z","phase":"Phase 2","brief_title":"Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer","source_id_and_acronym":"NCT01709292","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/07/2012","start_date":" 11/07/2012","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-05-21"},{"id":"82dcc018-99ce-47f7-8c3b-045c9ebf3e1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03220035","created_at":"2021-01-18T15:53:33.764Z","updated_at":"2024-07-02T16:35:02.750Z","phase":"Phase 2","brief_title":"Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03220035","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4","initiation":"Initiation: 11/08/2017","start_date":" 11/08/2017","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-05-17"},{"id":"a78b33a3-01e4-47a2-a800-be3b90f90ba4","acronym":"MODUL","url":"https://clinicaltrials.gov/study/NCT02291289","created_at":"2021-01-18T10:48:03.897Z","updated_at":"2025-02-25T14:00:31.914Z","phase":"Phase 2","brief_title":"A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)","source_id_and_acronym":"NCT02291289 - MODUL","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Herceptin (trastuzumab) • Erbitux (cetuximab) • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • 5-fluorouracil • Perjeta (pertuzumab) • Cotellic (cobimetinib) • capecitabine • oxaliplatin • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 1044","initiation":"Initiation: 04/17/2015","start_date":" 04/17/2015","primary_txt":" Primary completion: 05/31/2019","primary_completion_date":" 05/31/2019","study_txt":" Completion: 03/24/2021","study_completion_date":" 03/24/2021","last_update_posted":"2024-05-06"},{"id":"69622ca4-3967-4dd1-94fb-bb4cbf2391b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03181100","created_at":"2021-01-17T18:00:20.904Z","updated_at":"2024-07-02T16:35:06.482Z","phase":"Phase 2","brief_title":"Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer","source_id_and_acronym":"NCT03181100","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Cotellic (cobimetinib) • albumin-bound paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/27/2017","start_date":" 07/27/2017","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-05-02"},{"id":"fba96961-c2b5-441c-84a0-51876bc0c2d2","acronym":"COLUMBUS","url":"https://clinicaltrials.gov/study/NCT01909453","created_at":"2021-01-17T17:33:15.479Z","updated_at":"2024-07-02T16:35:07.254Z","phase":"Phase 3","brief_title":"Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma","source_id_and_acronym":"NCT01909453 - COLUMBUS","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 921","initiation":"Initiation: 09/16/2013","start_date":" 09/16/2013","primary_txt":" Primary completion: 11/09/2016","primary_completion_date":" 11/09/2016","study_txt":" Completion: 07/15/2024","study_completion_date":" 07/15/2024","last_update_posted":"2024-04-26"},{"id":"4338d698-1e9d-40b2-bf15-b2e998c85782","acronym":"Tricotel","url":"https://clinicaltrials.gov/study/NCT03625141","created_at":"2021-01-18T17:48:32.004Z","updated_at":"2024-07-02T16:35:10.102Z","phase":"Phase 2","brief_title":"A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases","source_id_and_acronym":"NCT03625141 - Tricotel","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 12/13/2018","start_date":" 12/13/2018","primary_txt":" Primary completion: 06/07/2021","primary_completion_date":" 06/07/2021","study_txt":" Completion: 04/13/2023","study_completion_date":" 04/13/2023","last_update_posted":"2024-04-11"},{"id":"5cf08ff0-036e-47fa-a6ae-ba545a8be1bd","acronym":"IMspire150","url":"https://clinicaltrials.gov/study/NCT02908672","created_at":"2021-01-17T17:17:34.789Z","updated_at":"2024-07-02T16:35:13.224Z","phase":"Phase 3","brief_title":"A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma","source_id_and_acronym":"NCT02908672 - IMspire150","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 514","initiation":"Initiation: 01/13/2017","start_date":" 01/13/2017","primary_txt":" Primary completion: 10/11/2019","primary_completion_date":" 10/11/2019","study_txt":" Completion: 05/15/2024","study_completion_date":" 05/15/2024","last_update_posted":"2024-03-22"},{"id":"251c6b33-0105-47ef-9273-5cf7a1f8bea7","acronym":"CRUKD/21/004","url":"https://clinicaltrials.gov/study/NCT05722886","created_at":"2023-02-10T15:00:24.135Z","updated_at":"2025-02-25T13:54:56.492Z","phase":"Phase 2/3","brief_title":"DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol","source_id_and_acronym":"NCT05722886 - CRUKD/21/004","lead_sponsor":"Cancer Research UK","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Perjeta (pertuzumab) • Cotellic (cobimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 825","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 10/01/2029","primary_completion_date":" 10/01/2029","study_txt":" Completion: 10/01/2029","study_completion_date":" 10/01/2029","last_update_posted":"2024-03-20"}]